RNA–lipid nanoparticles for acute critical illnesses
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior · Hepatitis Viruses Studies and Epidemiology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Yeh, T.-F., Lin, C. & Sung, H.-C. A review of technological developments in lipid nanoparticle application for mRNA vaccination. Hum. Vaccin. Immunother. 19, 2256040 (2023).10.1080/21645515.2023.2256040 ↗
2. Jeong, M., Lee, Y., Park, J., Jung, H. & Lee, H. Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications. Adv. Drug Deliv. Rev. 200, 114990 (2023).10.1016/j.addr.2023.114990 ↗
3. Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 7, 166 (2022).10.1038/s41392-022-01007-w ↗
4. Seo, Y. et al. Recent progress of lipid nanoparticles-based lipophilic drug delivery: focus on surface modifications. Pharmaceutics 15, 772 (2023).10.3390/pharmaceutics15030772 ↗
5. Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11–21 (2018).10.1056/NEJMoa1716153 ↗
6. Urits, I. et al. A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol. Ther. 9, 301–315 (2020).10.1007/s40120-020-00208-1 ↗
7. Fortner, A. & Schumacher, D. First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization. Discoveries 9, e122 (2021).10.15190/d.2021.1 ↗
8. Cyranoski, D. Why emergency COVID-vaccine approvals pose a dilemma for scientists. Nature 588, 18–19 (2020).10.1038/d41586-020-03219-y ↗
9. Precision Nanosystems. RNA-LNPs: Navigating the Regulatory Challenges. https://www.pharmaceutical-technology.com/sponsored/rna-lnps-navigating-the-regulatory-challenges/ (2023).
10. Centers for Disease Control and Prevention. Leading Causes of Death https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm (2024).
11. Centers for Disease Control and Prevention. Cancer Deaths — Health, United States https://www.cdc.gov/nchs/hus/topics/cancer-deaths.htm (2023).
12. Lüscher, T. F. Lumpers and splitters: the bumpy road to precision medicine. Eur. Heart J. 40, 3292–3296 (2019).10.1093/eurheartj/ehz644 ↗
13. Dhir, N. et al. Pre-clinical to clinical translational failures and current status of clinical trials in stroke therapy: a brief review. Curr. Neuropharmacol. 18, 596–612 (2020).10.2174/1570159X18666200114160844 ↗
14. Morales Castro, D., Dresser, L., Granton, J. & Fan, E. Pharmacokinetic alterations associated with critical illness. Clin. Pharmacokinet. 62, 209–220 (2023).10.1007/s40262-023-01213-x ↗
15. Hwang, T. J. et al. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern. Med. 176, 1826–1833 (2016).10.1001/jamainternmed.2016.6008 ↗
16. Maslove, D. M. et al. Redefining critical illness. Nat. Med. 28, 1141–1148 (2022).10.1038/s41591-022-01843-x ↗
17. Liu, P. et al. Subphenotyping heterogeneous patients with chronic critical illness to guide individualised fluid balance treatment using machine learning: a retrospective cohort study. EClinicalMedicine 59, 101970 (2023).10.1016/j.eclinm.2023.101970 ↗
18. Pirracchio, R. & Gropper, M. A. Heterogeneity in intensive care: low severity does not mean low risk! Anesthesiology 130, 190–191 (2019).10.1097/ALN.0000000000002537 ↗
19. Leligdowicz, A. & Matthay, M. A. Heterogeneity in sepsis: new biological evidence with clinical applications. Crit. Care 23, 80 (2019).10.1186/s13054-019-2372-2 ↗
20. Capra, E. et al. What early-stage investing reveals about biotech innovation. McKinsey & Company https://www.mckinsey.com/industries/life-sciences/our-insights/what-early-stage-investing-reveals-about-biotech-innovation (2023).
21. Quentin, W. et al. How Denmark, England, Estonia, France, Germany, and the USA pay for variable, specialized and low volume care: a cross-country comparison of in-patient payment systems. Int. J. Health Policy Manag. 11, 2940–2950 (2022).
22. Heine, R. et al. Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future. HemaSphere 5, e524 (2021).10.1097/HS9.0000000000000524 ↗
23. Villar, J. et al. Unsuccessful and successful clinical trials in acute respiratory distress syndrome: addressing physiology-based gaps. Front. Physiol. 12, 774025 (2021).10.3389/fphys.2021.774025 ↗
24. Radloff, K. et al. Cationic LNP-formulated mRNA expressing Tie2-agonist in the lung endothelium prevents pulmonary vascular leakage. Mol. Ther. Nucleic Acids 34, 102068 (2023).10.1016/j.omtn.2023.102068 ↗
25. Sun, H. et al. Application of lung-targeted lipid nanoparticle-delivered mRNA of soluble PD-L1 via SORT technology in acute respiratory distress syndrome. Theranostics 13, 4974–4992 (2023).10.7150/thno.86466 ↗
26. Tang, C. et al. mRNA-laden lipid-nanoparticle-enabled in situ CAR-macrophage engineering for the eradication of multidrug-resistant bacteria in a sepsis mouse model. ACS Nano 18, 2261–2278 (2024).10.1021/acsnano.3c10109 ↗
27. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05659264 (2025).
28. Pires, D. E. V., Blundell, T. L. & Ascher, D. B. PkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58, 4066–4072 (2015).10.1021/acs.jmedchem.5b00104 ↗
29. Jang, G. R., Harris, R. Z. & Lau, D. T. Pharmacokinetics and its role in small molecule drug discovery research. Med. Res. Rev. 21, 382–396 (2001).10.1002/med.1015 ↗
30. Sharma, A. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154, 123–140 (1997).10.1016/S0378-5173(97)00135-X ↗
31. Li, T., Cipolla, D., Rades, T. & Boyd, B. J. Drug nanocrystallisation within liposomes. J. Control. Release 288, 96–110 (2018).10.1016/j.jconrel.2018.09.001 ↗
32. Liu, P., Chen, G. & Zhang, J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules 27, 1372 (2022).10.3390/molecules27041372 ↗
33. Porello, I. & Cellesi, F. Intracellular delivery of therapeutic proteins. New advancements and future directions. Front. Bioeng. Biotechnol. 11, 1211798 (2023).10.3389/fbioe.2023.1211798 ↗
34. Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655–672 (2014).10.1038/nrd4363 ↗
35. Scaletti, F. et al. Protein delivery into cells using inorganic nanoparticle-protein supramolecular assemblies. Chem. Soc. Rev. 47, 3421–3432 (2018).10.1039/C8CS00008E ↗
36. Rahban, M. et al. Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry. RSC Adv. 13, 35947–35963 (2023).10.1039/D3RA06476J ↗
37. Wu, J., Sahoo, J. K., Li, Y., Xu, Q. & Kaplan, D. L. Challenges in delivering therapeutic peptides and proteins: a silk-based solution. J. Control. Release 345, 176–189 (2022).10.1016/j.jconrel.2022.02.011 ↗
38. Ball, R. L., Hajj, K. A., Vizelman, J., Bajaj, P. & Whitehead, K. A. Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA. Nano Lett. 18, 3814–3822 (2018).10.1021/acs.nanolett.8b01101 ↗
39. van der Meel, R. et al. Modular lipid nanoparticle platform technology for siRNA and lipophilic prodrug delivery. Small 17, e2103025 (2021).10.1002/smll.202103025 ↗
40. Kularatne, R. N., Crist, R. M. & Stern, S. T. The future of tissue-targeted lipid nanoparticle-mediated nucleic acid delivery. Pharmaceuticals 15, 897 (2022).10.3390/ph15070897 ↗
41. Nakamura, T. et al. Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines. Adv. Drug Deliv. Rev. 188, 114417 (2022).10.1016/j.addr.2022.114417 ↗
42. Xiao, Y. & Shi, J. Lipids and the emerging RNA medicines. Chem. Rev. 121, 12109–12111 (2021).10.1021/acs.chemrev.1c00778 ↗
43. Eygeris, Y., Gupta, M., Kim, J. & Sahay, G. Chemistry of lipid nanoparticles for RNA delivery. ACC Chem. Res. 55, 2–12 (2022).10.1021/acs.accounts.1c00544 ↗
44. Rietwyk, S. & Peer, D. Next-generation lipids in RNA interference therapeutics. ACS Nano 11, 7572–7586 (2017).10.1021/acsnano.7b04734 ↗
45. Landesman-Milo, D. & Peer, D. Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. Drug Deliv. Transl. Res. 4, 96–103 (2014).10.1007/s13346-013-0158-7 ↗
46. Peer, D. Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv. Drug Deliv. Rev. 64, 1738–1748 (2012).10.1016/j.addr.2012.06.013 ↗
47. Chatterjee, S., Kon, E., Sharma, P. & Peer, D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc. Natl Acad. Sci. USA 121, e2307800120 (2024).10.1073/pnas.2307800120 ↗
48. Gilleron, J. et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638–646 (2013).10.1038/nbt.2612 ↗
49. Ma, D. Enhancing endosomal escape for nanoparticle mediated siRNA delivery. Nanoscale 6, 6415–6425 (2014).10.1039/c4nr00018h ↗
50. Pattipeiluhu, R. et al. Liquid crystalline inverted lipid phases encapsulating siRNA enhance lipid nanoparticle mediated transfection. Nat. Commun. 15, 1303 (2024).10.1038/s41467-024-45666-5 ↗
51. Philipp, J. et al. pH-dependent structural transitions in cationic ionizable lipid mesophases are critical for lipid nanoparticle function. Proc. Natl Acad. Sci. USA 120, e2310491120 (2023).10.1073/pnas.2310491120 ↗
52. Eygeris, Y., Patel, S., Jozic, A. & Sahay, G. Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nano Lett. 20, 4543–4549 (2020).10.1021/acs.nanolett.0c01386 ↗
53. Heyes, J., Palmer, L., Bremner, K. & MacLachlan, I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107, 276–287 (2005).10.1016/j.jconrel.2005.06.014 ↗
54. Han, X. et al. An ionizable lipid toolbox for RNA delivery. Nat. Commun. 12, 7233 (2021).10.1038/s41467-021-27493-0 ↗
55. Cheng, X. & Lee, R. J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv. Drug Deliv. Rev. 99, 129–137 (2016).10.1016/j.addr.2016.01.022 ↗
56. Hald Albertsen, C. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 188, 114416 (2022).10.1016/j.addr.2022.114416 ↗
57. Wilson, B. & Geetha, K. M. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. J. Drug Deliv. Sci. Technol. 74, 103553 (2022).10.1016/j.jddst.2022.103553 ↗
58. Kawaguchi, M. et al. Effect of cholesterol content of lipid composition in mRNA-LNPs on the protein expression in the injected site and liver after local administration in mice. J. Pharm. Sci. 112, 1401–1410 (2023).10.1016/j.xphs.2022.12.026 ↗
59. Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).10.1038/s41467-020-14527-2 ↗
60. Wang, M. M. et al. Elucidation of lipid nanoparticle surface structure in mRNA vaccines. Sci. Rep. 13, 16744 (2023).10.1038/s41598-023-43898-x ↗
61. Berger, M. et al. Effect of PEG anchor and serum on lipid nanoparticles: development of a nanoparticles tracking method. Pharmaceutics 15, 597 (2023).10.3390/pharmaceutics15020597 ↗
62. Sarode, A. et al. Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing. Nanoscale Adv. 4, 2107–2123 (2022).10.1039/D1NA00712B ↗
63. Lee, Y., Jeong, M., Park, J., Jung, H. & Lee, H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 55, 2085–2096 (2023).10.1038/s12276-023-01086-x ↗
64. Tenchov, R., Sasso, J. M. & Zhou, Q. A. PEGylated lipid nanoparticle formulations: Immunological safety and efficiency perspective. Bioconjug. Chem. 34, 941–960 (2023).10.1021/acs.bioconjchem.3c00174 ↗
65. Parhiz, H. et al. PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake. J. Control. Release 291, 106–115 (2018).10.1016/j.jconrel.2018.10.015 ↗
66. Tombácz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Mol. Ther. 29, 3293–3304 (2021).10.1016/j.ymthe.2021.06.004 ↗
67. Lokugamage, M. P. et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 5, 1059–1068 (2021).10.1038/s41551-021-00786-x ↗
68. Del Sorbo, L. & Slutsky, A. S. Acute respiratory distress syndrome and multiple organ failure. Curr. Opin. Crit. Care 17, 1–6 (2011).
69. Silva, P. L., Pelosi, P. & Rocco, P. R. M. Personalized pharmacological therapy for ARDS: a light at the end of the tunnel. Expert Opin. Investig. Drugs 29, 49–61 (2020).10.1080/13543784.2020.1699531 ↗
70. Wilson, J. G. & Calfee, C. S. in Annual Update in Intensive Care and Emergency Medicine 2020 (ed Vincent, J.-L.) 67–79 (Springer International Publishing, 2020).10.1007/978-3-030-37323-8_5 ↗
71. Rezoagli, E. et al. Presence of comorbidities alters management and worsens outcome of patients with acute respiratory distress syndrome: insights from the LUNG SAFE study. Ann. Intensive Care 12, 42 (2022).10.1186/s13613-022-01015-7 ↗
72. Melamed, J. R. et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer. Sci. Adv. 9, eade1444 (2023).10.1126/sciadv.ade1444 ↗
73. Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).10.1073/pnas.2109256118 ↗
74. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).10.1038/s41565-020-0669-6 ↗
75. Torchilin, V. P., Khaw, B. A., Smirnov, V. N. & Haber, E. Preservation of antimyosin antibody activity after covalent coupling to liposomes. Biochem. Biophys. Res. Commun. 89, 1114–1119 (1979).10.1016/0006-291X(79)92123-5 ↗
76. Heath, T. D., Fraley, R. T. & Papahdjopoulos, D. Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab’)2 to vesicle surface. Science 210, 539–541 (1980).10.1126/science.7423203 ↗
77. Gregoriadis, G. Targeting of drugs. Nature 265, 407–411 (1977).10.1038/265407a0 ↗
78. Zamora, M. E. et al. Combination of physicochemical tropism and affinity moiety targeting of lipid nanoparticles enhances organ targeting. Nano Lett. https://doi.org/10.1021/acs.nanolett.3c05031 (2024).10.1021/acs.nanolett.3c05031 ↗
79. Marcos-Contreras, O. A. et al. Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain. J. Control. Release 301, 54–61 (2019).10.1016/j.jconrel.2019.03.008 ↗
80. Ferrer, M. C. C. et al. ICAM-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation. PLoS One 9, e102329 (2014).10.1371/journal.pone.0102329 ↗
81. Nong, J. et al. Targeting lipid nanoparticles to the blood brain barrier to ameliorate acute ischemic stroke. Mol. Ther. https://doi.org/10.1016/j.ymthe.2024.03.004 (2024).10.1016/j.ymthe.2024.03.004 ↗
82. Omo-Lamai, S. et al. Targeting of nanoparticles to the cerebral vasculature after traumatic brain injury. PLoS One 19, e0297451 (2024).10.1371/journal.pone.0297451 ↗
83. Zamora, M. E. et al. Marginated neutrophils in the lungs effectively compete for nanoparticles targeted to the endothelium, serving as a part of the reticuloendothelial system. ACS Nano 18, 22275–22297 (2024).10.1021/acsnano.4c06286 ↗
84. Muzykantov, V. R. et al. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc. Natl Acad. Sci. USA 96, 2379–2384 (1999).10.1073/pnas.96.5.2379 ↗
85. Brenner, J. S., Greineder, C., Shuvaev, V. & Muzykantov, V. Endothelial nanomedicine for the treatment of pulmonary disease. Expert Opin. Drug Deliv. 12, 239–261 (2015).10.1517/17425247.2015.961418 ↗
86. Marcos-Contreras, O. A. et al. Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier. Proc. Natl Acad. Sci. USA 117, 3405–3414 (2020).10.1073/pnas.1912012117 ↗
87. Asgeirsdóttir, S. A. et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am. J. Physiol. Renal Physiol. 294, F554–F561 (2008).10.1152/ajprenal.00391.2007 ↗
88. Feuerhake, F., Füchsl, G., Bals, R. & Welsch, U. Expression of inducible cell adhesion molecules in the normal human lung: immunohistochemical study of their distribution in pulmonary blood vessels. Histochem. Cell Biol. 110, 387–394 (1998).10.1007/s004180050299 ↗
89. Myerson, J. W. et al. Flexible nanoparticles reach sterically obscured endothelial targets inaccessible to rigid nanoparticles. Adv. Mater. 30, e1802373 (2018).10.1002/adma.201802373 ↗
90. Myerson, J. W. et al. Supramolecular arrangement of protein in nanoparticle structures predicts nanoparticle tropism for neutrophils in acute lung inflammation. Nat. Nanotechnol. 17, 86–97 (2022).10.1038/s41565-021-00997-y ↗
91. Wang, Z. et al. Combating complement’s deleterious effects on nanomedicine by conjugating complement regulatory proteins to nanoparticles. Adv. Mater. 34, e2107070 (2022).10.1002/adma.202107070 ↗
92. Wang, Z. & Brenner, J. S. The nano-war against complement proteins. AAPS J. 23, 105 (2021).10.1208/s12248-021-00630-9 ↗
93. Lopes dos Santos, M., Quintilio, W., Manieri, T. M., Tsuruta, L. R. & Moro, A. M. Advances and challenges in therapeutic monoclonal antibodies drug development. Braz. J. Pharm. Sci. 54, e01007 (2018).
94. Xu, L. et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 1, 337–346 (2002).
95. Hood, E. D. et al. Vascular targeting of radiolabeled liposomes with bio-orthogonally conjugated ligands: single chain fragments provide higher specificity than antibodies. Bioconjug. Chem. 29, 3626–3637 (2018).10.1021/acs.bioconjchem.8b00564 ↗
96. Thomas, G. D. Effect of dose, molecular size, and binding affinity on uptake of antibodies. Methods Mol. Med. 25, 115–132 (2000).
97. Janeway, C. A., Jr, Travers, P., Walport, M. & Shlomchik, M. J. in Immunobiology: The Immune System in Health and Disease 5th edn (Garland Science, 2001).
98. Chames, P., Van Regenmortel, M., Weiss, E. & Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future: therapeutic antibodies: an update. Br. J. Pharmacol. 157, 220–233 (2009).10.1111/j.1476-5381.2009.00190.x ↗
99. Wilkinson, I. et al. Fc-engineered antibodies with immune effector functions completely abolished. PLoS One 16, e0260954 (2021).10.1371/journal.pone.0260954 ↗
100. Yu, W. et al. Efficient labeling of native human IgG by proximity-based sortase-mediated isopeptide ligation. Bioconjug. Chem. 32, 1058–1066 (2021).10.1021/acs.bioconjchem.1c00099 ↗